Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Bystronic AG
  6. News
  7. Summary
    BYS   CH0244017502


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exclusive: German artificial limb maker Ottobock plans blockbuster 2022 IPO - sources

07/08/2021 | 11:52am EDT
FILE PHOTO: A bebionic hand is seen during the Ottobock media day in Vienna

FRANKFURT (Reuters) - Ottobock is preparing for a blockbuster stock market flotation in 2022 that could value the German artificial limb maker at more than 5 billion euros ($5.9 billion), three people close to the matter said.

The company, 80% owned by the founding Naeder family and 20% by buyout fund EQT, has asked banks to pitch for roles in the initial public offering, which could become one of the country's largest deals next year.

Ottobock, which was founded in 1919 as a maker of prosthesis for World War One veterans, has repeatedly said it eventually plans to go public, but has so far not commented on the expected timing of a deal.

"We want to be capital markets ready from 2022. Work towards that milestone is ongoing," said a spokesman for the Duderstadt-based company on Thursday, declining to elaborate.

Ottobock's family owners and EQT declined to comment.

The mandating of banks to prepare for an IPO often takes place at least 3-6 months ahead of any deal, and final timing depends on market conditions that need to be favorable for any transaction to go ahead.

The company makes prosthetics, orthotics, wheelchairs and exoskeletons and in 2019 posted core earnings of 191 million euros on sales of 1 billion euros. Last year, it saw revenues drop as shops remained closed during the COVID-19 pandemic.

Listed peers include Ossur, Hanger Invacare and Ekso Bionics.

According to market research, the global $6 billion prosthesis and orthosis market is expected to grow by about 4% annually as populations age and cases of injuries as well as of diseases like bone cancer rise.

While Ottobock has been considering an IPO for years, EQT's stake purchase in 2017 at a valuation of 3.15 billion euros delayed earlier plans.

Since the buyout group's investment, Ottobock has named former Fresenius manager Philip Schulte-Noelle as Chief Executive.

It has also sold off its plastic foam materials business to Switzerland's Conzzeta and acquired businesses such as V!GO, assets of peer Freedom Innovations and a stake in distributor Cascade Orthopedic Supply.

($1 = 0.8431 euros)

(Reporting by Arno Schuetze; Editing by Kirsten Donovan)

By Arno Schuetze

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BYSTRONIC AG -0.89% 1340 Delayed Quote.23.16%
EKSO BIONICS HOLDINGS, INC. 0.52% 4.6942 Delayed Quote.-23.42%
EQT AB (PUBL) -4.60% 371.1 Delayed Quote.76.38%
FRESENIUS SE & CO. KGAA -0.47% 41.12 Delayed Quote.8.67%
ÖSSUR HF. -0.44% 45.6 Delayed Quote.-5.88%
All news about BYSTRONIC AG
09/10BYSTRONIC : presentation UBS Best of Switzerland Conference 2021 (EN)
09/10BYSTRONIC : Investora Conference Presentation, September 2021 (EN)
08/16BYSTRONIC : Credit Suisse Lifts Price Target on Bystronic, Maintains Outperform Recommenda..
08/06EQS-ADHOC : Bystronic AG: Half-Year Report 2021 -2-
08/06EQS-ADHOC : Bystronic AG: Half-Year Report 2021
08/06Bystronic AG Provides Sales Guidance for the Year 2021
08/05Bystronic Ag Reports Earnings Results for the Half Year Ended June 30, 2021
07/09FTSE 100 Stages a Turnaround to End Friday with Gains
07/09FTSE Gains, Bunzl's Prospects Are Better Than The Market Thinks
07/08EXCLUSIVE : German artificial limb maker Ottobock plans blockbuster 2022 IPO - sources
More news
Analyst Recommendations on BYSTRONIC AG
More recommendations
Sales 2021 1 011 M 1 093 M 1 093 M
Net income 2021 14,6 M 15,8 M 15,8 M
Net cash 2021 507 M 549 M 549 M
P/E ratio 2021 187x
Yield 2021 1,66%
Capitalization 2 771 M 2 995 M 2 997 M
EV / Sales 2021 2,24x
EV / Sales 2022 2,17x
Nbr of Employees 3 357
Free-Float 70,3%
Duration : Period :
Bystronic AG Technical Analysis Chart | BYS | CH0244017502 | MarketScreener
Technical analysis trends BYSTRONIC AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 1 340,00 CHF
Average target price 1 423,00 CHF
Spread / Average Target 6,19%
EPS Revisions
Managers and Directors
Alex Waser Chief Executive Officer
Beat Neukom Chief Financial Officer
Ernst J. Bńrtschi Chairman
Jacob Schmidheiny Director
Matthias Auer Director
Sector and Competitors